Regulatory context
Primary evidence or regulator source
No matched treatment-outcome population.
Reported findings. No benefit claim from this context reference.
Nonresponse. Not reported in reviewed excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Context citations do not fill outcome-evidence gaps.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Product label
Vyleesi bremelanotide injection label; PI revised March 2024, DailyMed updated November 13, 2025
Premenopausal women with acquired generalized HSDD. Label efficacy section randomizes 635 + 632 = 1267; safety section describes 1247 treated. Endpoint-specific modified-intent-to-treat counts differ.
Reported findings. Two 24-week randomized placebo-controlled trials reported mean desire-score changes of +0.5/+0.6 versus +0.2 with placebo, and distress-score changes of -0.7 versus -0.4. Scores and scales differ.
Nonresponse. Satisfying-sexual-event counts, a secondary endpoint, did not differ significantly: p=.76/.70. Premature all-cause MITT discontinuation was 40% versus 13% and 39% versus 25%; this is not an adverse-event-only or nonresponse rate.
Harms. Adverse-reaction discontinuation was 18% versus 2% with placebo. Nausea, flushing, injection-site reactions, headache/vomiting, transient blood-pressure/heart-rate changes and focal hyperpigmentation are reported.
Limits. Subcutaneous Vyleesi in this population only; no transfer to men, postmenopausal women, general performance or other preparations/routes. Endpoint-specific evaluable MITT denominators differ; randomized, treated/safety and completion counts are not interchangeable. DailyMed updated 2025-11-13; PI revised 2024-03. Neither is an invented original webpage publication date.
Preparation: Vyleesi bremelanotide injection Route: subcutaneous
Read original source ↗Editorial review 2026-10-15. Clinician review pending.